Trial reportSchizophrenia research2008
Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects.
Trial report in Schizophrenia research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00903916 (Effect of Weight-increasing Psychotropic Medications on Appetite Regulation), which is not on this map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Weight-increasing Psychotropic Medications on Appetite Regulation
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Almost all antipsychotics result in weight gain: a meta-analysis.PloS one · 2014 · on this mapPooled it
- Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients.Schizophrenia bulletin · 2013Pooled it
- The association between antipsychotic agents and the risk of myocardial infarction: a systematic review.British journal of clinical pharmacology · 2011Pooled it
- Effect of lurasidone versus olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia: a randomized controlled trial.Psychopharmacology · 2020Trial
- Crosstalk between Schizophrenia and Metabolic Syndrome: The Role of Oxytocinergic Dysfunction.International journal of molecular sciences · 2022Review
- Unveiling the Metabolic Profile of First-Episode Drug-Naïve Schizophrenia Patients: Baseline Characteristics of a Longitudinal Study Among Han Chinese.Frontiers in psychiatry · 2021Article
- Reduced levels of circulating adhesion molecules in adolescents with early-onset psychosis.NPJ schizophrenia · 2020Article
- Blood-brain barrier pathology in patients with severe mental disorders: a systematic review and meta-analysis of biomarkers in case-control studies.Brain, behavior, & immunity - health · 2020Article
- Predictive factors for hyperglycaemic progression in patients with schizophrenia or bipolar disorder.BJPsych open · 2018Article
- Long-Term Evolution of Metabolic Status in Patients with Schizophrenia Stably Maintained on Second-Generation Antipsychotics.Psychiatry investigation · 2018Article
- Cardiovascular Risk in Early Psychosis: Relationship with Inflammation and Clinical Features 6 Months after Diagnosis.The international journal of neuropsychopharmacology · 2018Article
- Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis.BMC health services research · 2018Article
- Diabetes mellitus and severe mental illness: mechanisms and clinical implications.Nature reviews. Endocrinology · 2015Review
- Neurodegenerative aspects in vulnerability to schizophrenia spectrum disorders.Neurotoxicity research · 2014Review
- A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2013Article
- Metabolic syndrome and bipolar disorder: what should psychiatrists know?CNS neuroscience & therapeutics · 2012Review
- Using internet enabled mobile devices and social networking technologies to promote exercise as an intervention for young first episode psychosis patients.BMC psychiatry · 2011Article
- Genetic associations of brain structural networks in schizophrenia: a preliminary study.Biological psychiatry · 2010Article
- Metabolic syndrome associated with schizophrenia and atypical antipsychotics.Current diabetes reports · 2010Review
- Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration.BMC psychiatry · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo examine prospective changes in cardiovascular disease (CVD) and type-2 diabetes risk factors in young adult first episode psychotic (FEP) patients treated with second generation antipsychotic medications.
methodsAt baseline, fasting serum and anthropometric measures were obtained from 45 FEP patients and 41 healthy adults (controls) of similar age, ethnicity and sex; sixteen of the FEP patients remained on the same antipsychotic medication and were available for a second blood draw at 24 weeks of treatment. Serum was assayed for glucose, insulin, triglycerides, total cholesterol and high and low density lipoproteins (HDL, LDL), adiponectin, leptin, interleukin 6, E-selectin and VCAM-1. Wilcoxon nonparametric tests were used to compare risk markers between the FEP and control group at baseline and to evaluate pre-post treatment changes within the FEP group.
resultsAt baseline, the distributions of risk marker values were similar between the two groups and the percentages of FEP patients and healthy controls who were overweight/obese, dyslipidemic, hyperglycemic, and hyperinsulinemic did not differ. At 24 weeks, compared to baseline, FEP patients showed significant increases in BMI (p=0.0002), glucose (p=0.0449), insulin (p=0.0161), cholesterol (p=0.0129), leptin (p=0.0215), and E-selectin (p=0.0195), and a decrease in adiponectin (p=0.0371).
conclusionsAmong patients with first episode psychosis, 6-month treatment with second generation antipsychotics is associated with the exacerbation of pre-existing and emergence of new CVD and diabetes risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.